{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oxaliplatin+Induced+Peripheral+Neuropathy+in+Cancer+Patients",
    "query": {
      "condition": "Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T00:32:34.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04137107",
      "title": "Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stage II Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2020-06-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 792,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04137107"
    },
    {
      "nct_id": "NCT05291286",
      "title": "BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuropathy;Peripheral",
        "Chemotherapy-induced Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-10-17",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05291286"
    },
    {
      "nct_id": "NCT00112996",
      "title": "Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neurotoxicity",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "alpha-lipoic acid",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 244,
      "start_date": "2007-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 13,
      "location_summary": "Fort Smith, Arkansas • Lafayette, Indiana • Wichita, Kansas + 10 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Alexandria",
          "state": "Louisiana"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112996"
    },
    {
      "nct_id": "NCT05251727",
      "title": "Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-induced Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "thrombomodulin alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2022-03-24",
      "completion_date": "2024-06-05",
      "has_results": false,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 18,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Norwich, Connecticut + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05251727"
    },
    {
      "nct_id": "NCT04505553",
      "title": "Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Appendix Carcinoma",
        "Colon Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Carcinoma",
        "Liver and Intrahepatic Bile Duct Carcinoma",
        "Malignant Digestive System Neoplasm",
        "Pancreatic Carcinoma",
        "Rectal Carcinoma",
        "Small Intestinal Carcinoma",
        "Anal Carcinoma",
        "Digestive System Carcinoma",
        "Digestive System Neuroendocrine Tumor",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Acupuncture Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Acupressure Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Oral Cryotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2021-06-01",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505553"
    },
    {
      "nct_id": "NCT00603577",
      "title": "Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Xaliproden",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2008-01",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2016-05-05",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603577"
    },
    {
      "nct_id": "NCT03654729",
      "title": "Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Chemotherapy-induced Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Calmangafodipir (2 µmol/kg)",
          "type": "DRUG"
        },
        {
          "name": "Calmangafodipir (5 µmol/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Egetis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 291,
      "start_date": "2018-11-07",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 11,
      "location_summary": "Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654729"
    },
    {
      "nct_id": "NCT07167446",
      "title": "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients",
        "Metastatic Colorectal Cancer (CRC)",
        "Peripheral Neuropathy Due to Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Cannabidiol (CBD)",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin-based chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-14",
      "completion_date": "2028-09-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-06-26T00:32:34.432Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167446"
    }
  ]
}